Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Molecular Profile||Indication/Tumor Type||Response Type||Relevant Treatment Approaches||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|CHEK1 inact mut||prostate cancer||sensitive||Olaparib||Olaparib||FDA approved - On Companion Diagnostic||Actionable||In a Phase III trial (PROfound) that supported FDA approval, Lynparza (olaparib) treatment significantly improved progression-free survival (PFS, 5.8 vs 3.5 mo, HR=0.49, p<0.001) compared to control in patients with metastatic castration-resistant prostate cancer harboring deleterious or suspected deleterious mutations in homologous recombination repair genes who progressed on hormone therapy, including patients harboring CHEK1 mutations (PMID: 32343890; NCT02987543).||detail... detail... 32343890|
|CHEK1 inact mut||prostate cancer||sensitive||Olaparib||Olaparib||Case Reports/Case Series||Actionable||In a Phase II (TOPARP-B) trial, Lynparza (olaparib) treatment resulted in a composite overall response rate of 20.0% (4/20) and a RECIST objective response rate of 0% (0/17) in patients with castration-resistant prostate cancer harboring deleterious mutations in DNA damage response genes, including ARID1A, ATRX, CHEK1/2, FANCA, FANCF, FANCG, FANCI, FANCM, MSH2, NBN, RAD50, and WRN (n=1, 1, 1, 5, 5, 2, 1, 1, 2, 1, 1, 1, 7, respectively) (PMID: 31806540; NCT01682772).||31806540|
|CHEK1 inact mut||prostate cancer||sensitive||Olaparib||Olaparib||Guideline||Actionable||Lynparza (olaparib) is included in guidelines as second-line therapy post androgen receptor-directed therapy for patients with metastatic castration-resistant prostate cancer harboring pathogenic mutations in CHEK1 (NCCN.org).||detail...|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|
|NCT04826341||Phase Ib/II||Berzosertib + Sacituzumab govitecan-hziy||A Phase I/II Study of Sacituzumab Govitecan Plus Berzosertib in Small Cell Lung Cancer and Homologous Recombination-Deficient Cancers Resistant to PARP Inhibitors||Recruiting||USA||0|
|NCT04985721||Phase II||Pamiparib + Tislelizumab||A Trial of Pamiparib With Tislelizumab in Patients With Advanced Tumours With Homologous Recombination Repair Defects (IMPARP-HRD)||Recruiting||1|
|NCT04983745||Phase II||Dostarlimab-gxly + Niraparib||Niraparib and Dostarlimab in HRD Solid Tumors (DIDO)||Not yet recruiting||USA||0|
|NCT05188508||Phase II||Olaparib + Pembrolizumab + Temozolomide||Pembrolizumab, Olaparib, and Temozolomide for People With Glioma||Recruiting||USA||0|
|NCT05038839||Phase I||Cabozantinib + Pamiparib||Cabozantinib and Pamiparib for the Treatment of Advanced of Refractory Solid Tumors||Recruiting||USA||0|
|NCT04053322||Phase II||Durvalumab + Fulvestrant + Olaparib||Durvalumab, With Olaparib and Fulvestrant in Advanced ER+, HER2- Breast Cancer Patients. (DOLAF)||Recruiting||FRA||0|
|NCT03209401||Phase I||Carboplatin + Niraparib||Niraparib Plus Carboplatin in Patients With Homologous Recombination Deficient Advanced Solid Tumor Malignancies||Recruiting||USA||0|
|NCT02734004||Phase Ib/II||Durvalumab + Olaparib Bevacizumab + Durvalumab + Olaparib||A Phase I/II Study of MEDI4736 in Combination With Olaparib in Patients With Advanced Solid Tumors. (MEDIOLA)||Completed||USA | FRA||5|
|NCT04253262||Phase Ib/II||Copanlisib + Rucaparib||A Study of Copanlisib Combined With Rucaparib in Patients With Metastatic Castration-resistant Prostate Cancer||Recruiting||USA||0|
|NCT03047135||Phase II||Olaparib||Olaparib in Men With High-Risk Biochemically-Recurrent Prostate Cancer Following Radical Prostatectomy, With Integrated Biomarker Analysis||Recruiting||USA||0|
|NCT03786796||Phase II||Olaparib||Study of Olaparib in Metastatic Renal Cell Carcinoma Patients With DNA Repair Gene Mutations (ORCHID)||Recruiting||USA||0|
|NCT04550494||Phase II||Talazoparib||Measuring the Effects of Talazoparib in Patients With Advanced Cancer and DNA Repair Variations||Recruiting||USA||0|
|NCT03377556||Phase II||Talazoparib||Lung-MAP: Talazoparib in Treating Patients With HRRD Positive Recurrent Stage IV Squamous Cell Lung Cancer||Completed||USA | CAN||0|
|NCT05071209||Phase Ib/II||BAY1895344||Elimusertib for the Treatment of Relapsed or Refractory Solid Tumors||Recruiting||USA||0|
|NCT05379972||Phase II||Olaparib + Pembrolizumab||Phase II Study of SBRT/Olaparib Followed by Pembrolizumab/Olaparib in Gastric Cancers||Not yet recruiting||USA||0|